Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ganitumab · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| ganitumab | BIOLOGICAL | - |
| laboratory biomarker analysis | OTHER | - |
| pharmacological study | OTHER | - |
| biopsy | PROCEDURE | - |
DISEASE CHARACTERISTICS: Inclusion criteria: * Histologically or cytologically confirmed advanced solid tumors or non-Hodgkin lymphoma that is refractory to standard treatment or for which no curative therapy is available * Tumor tissue that is accessible for biopsy by using minimally invasive pro...
Top 20 of 66 competitors
Ganitumab is an investigational monoclonal antibody being studied for the treatment of lymphoma, specifically in patients with advanced solid tumors or non-Hodgkin lymphoma. It is being developed by Amgen Inc. as an oncology therapy.
Ganitumab is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is an investigational monoclonal antibody in clinical development for oncology indications.
Ganitumab is in Phase 1 clinical development. It has completed one Phase 1 trial, and it remains an investigational drug that has not been approved by regulatory authorities. The drug is being studied for its safety and tolerability in patients with advanced solid tumors or non-Hodgkin lymphoma.
Ganitumab has been studied in one completed Phase 1 clinical trial with the identifier NCT00562380. This trial, titled 'AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma,' enrolled 64 participants in the United States and was an uncontrolled, randomized study.
Ganitumab is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it has not received regulatory approval. The drug remains in clinical development for the treatment of lymphoma and other advanced solid tumors.